sellModerate cluster of 6
William Richard White sold $30k of AKRO
Chief Financial Officer at Akero Therapeutics, Inc.. 676 shares at an average of $44.88, traded Mar 12, 2025, filed Mar 14, 2025.
Warning score
42Value
$30k
676 shares
Holdings after
61,959
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +5Trade size$30k at market
- 0Share of holdings soldSold 1.1% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-039734, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 12, 2025 | SOpen-market sale Common Stock | -676 | $44.88 | $30k | 61,959 | Mar 14, 2025 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 5Weak | Akero Therapeutics, Inc. | Patrick Lamy Senior VP, Commercial Strategy | $108k 2,000 shares | -6% | |
| 14Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $542k 10,000 shares | -10% | |
| 44Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $80k 1,453 shares | -1% | |
| 39Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $90k 1,633 shares | -2% | |
| 46Moderate | Akero Therapeutics, Inc. | William Richard White Chief Financial Officer | $90k 1,634 shares | -3% | |
| 37Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $62k 1,129 shares | -1% | |
| 37Weak | Akero Therapeutics, Inc. | Patrick Lamy Senior VP, Commercial Strategy | $48k 875 shares | -3% | |
| 36Weak | Akero Therapeutics, Inc. | Scott A. Gangloff Chief Technology Officer | $47k 848 shares | -3% | |
| 55Moderate | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $363k 6,620 shares | -1% | |
| 46Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $135k 2,493 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.